Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets

@inproceedings{Prada2018TargetedTO,
  title={Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets},
  author={Elke Tatjana Aristizabal Prada and Christoph J. Auernhammer},
  booktitle={Endocrine connections},
  year={2018}
}
Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the gastroenteropancreatic (GEP) system currently encompasses approved therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib. However, clinical efficacy of these treatment strategies is limited by low objective response rates and limited progression-free survival due to tumour resistance. Further novel strategies for molecular targeted therapy of NETs of… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 259 REFERENCES